ABSTRACT
INTRODUCTION
Cytomegaloviras (CMV) is an ubiquitous human herpes virus which causes one of the most important life-threatening opportunistic infections in individuals with impaired immune system. Although CMV infection is asymptomatic in most healthy individuals, it could be reactivated in immunosuppressed hosts, such as organ transplant recipients and patients with AIDS, causing significant morbidity and mortality. CMV retinitis has become the most common infectious ocular disease associated with AIDS, affecting 12 to 46% of AIDS patients (1). It induces a necrotic retinitis that quickly progresses to total retinal destruction and blindness in less than six months if untreated (2) . The major life-threatening nature of CMV-related diseases in high risk individuals denotes the need for a safe and appropriate treatment of CMV infections.
Foscamet (phosphonoformic acid, PFA) is a pyrophosphate analogue which prevents the replication of human herpes viruses, including CMV, by inhibiting viral DNA polymerases through noncompetitive interaction with viral enzymes at the pyrophosphate binding sites (3) . This drag has been approved by the Food and Drag Administration (FDA) for the treatment of CMV retinitis in patients with AIDS (4) . It can also inhibit human immunodeficiency virus (HIV) reverse transcriptase (5) (6) (7) . Combined with zidovudine (AZT), foscamet is synergistic against HIV (8) . In contrast to nucleoside analogues, foscamet does not have to be phosphorylated intracellularly to be active against HIV or CMV. This difference is of importance as one of the major mechanisms of resistance developed by microorganisms, such as CMV or other members of the herpes family, is their capacity to mutate and modify or eliminate phosphorylation of the antiviral agents within infected cells. Because of the poor bioavailability of foscamet when taken orally and its low cellular permeability, large doses of foscamet have to be administered intravenously to patients to be active. Induction treatments with intravenous foscamet can stop the progression of the infection for a while, but reactivation occurs in a high percentage of cases. This is most probably due to the poor penetration of the drag into the eye cavity through the blood retinal barrier (9) which can account for antiviral resistance. Foscamet is not metabolized, and 83% of a cumulative intravenous dose is recovered unchanged in the urine during the first 36 hours after stopping the infusion (4) .
An important problem associated with prolonged maintenance therapy of foscamet is its toxicity. The most frequent dose-limiting adverse effects associated with intravenous foscarnet therapy are renal impairment and alterations in plasma minerals and electrolytes (4, 10, 11) . A 2-to 3-fold increase in serum creatinine has been observed in 20-66% of AIDS patients receiving 130 to 230 mg/kg/day of foscamet as a continuous infusion (4, 10, 12) ; hemodialysis may be required in severe cases of renal impairment. This nephrotoxicity is believed to be due to acute tubular necrosis or interstitial tubular nephritis which tends to be reversible on foscamet withdrawal. Reversible calcium and phosphorus abnormalities (both increases and decreases were reported) have been observed in foscamet recipients (11, (13) (14) (15) . Therapy with this antiviral is also associated with anemia in 20-50% of AIDS patients (13, 16, 17) . Because of the severe toxicity of foscamet, treatment is commonly stopped, resulting in a retinitis relapse.
A well-defined animal model would be very useful to evaluate the efficacy of antiviral agents against CMV retinitis. Unfortunately, human CMV is a species-specific virus which is not transmissible to animals (18) . Presently, no successful infection with human CMV has been reported in animal models. Therefore, we have chosen the human Herpes simplex virus type-1 (HSV-l)-KOS strain to induce retinitis in the rabbit model. This model has been previously used to evaluate the clinical efficacy of antiviral drugs (19, 20 (24) .
Effect of Intravitreal Foscamet on Viral Titers
The viral titration in tissues of untreated infected and foscamet-treated rabbits is shown in figure  1 . Results clearly showed a significant reduction in the HSV-1 counts in the infected chorioretinae ( Figure 1A) (Figure IB ), no significant difference was observed between the two groups, with 2/6 and 1/6 eyes below the detection limit for the untreated infected and infected+PFA groups, respectively. In the optic chiasm ( Figure 1C) , the difference was also not significant between the two groups, with 3/6 and 4/6 eyes below the detection limit for the untreated infected and infected+PFA groups, respectively. Although no significant difference was observed, the virus titer was lower in the foscamet treated group compared to the untreated infected one. The virus was not found in the hemispheres or the cerebella of any of the animals in either treatment group. The limits of detection for the viral titration were 1.82 log pfu/ml (and pfu/g) for the chorioretina and optic chiasm, and 1.52 log pfu/ml for the vitreous.
Histopathologic Examination and Immunolocalization
The whole retina of each group was used for histopathologic examination and immunolocalization. Figure 2 shows typical micrographs of chorioretinae of each group. The retina of uninfected rabbits (Figure 2A) showed that the ganglion cell layer (GCL), the inner nuclear layer (INL) and the outer nuclear layer (ONL) were not damaged. On the other hand, the histology of the retina of infected rabbits ( Figure 2C ) demonstrated a massive destruction. It was indeed difficult to identify the GCL, and there was clear infiltration of inflammatory cells in the INL and ONL. In contrast, there was no damage in infected rabbits that were treated with foscamet ( Figure 2E ). The retinal layers were well preserved and were comparable to that of uninfected controls. However, we observed some inflammatory cells in the vitreous. The immunolocalization of HSV in the retina clearly showed infected cells in the INL and ONL as well as in the GCL of untreated infected rabbits ( Figure 2D) . No virus was immunolocalized in the retina of the uninfected group ( Figure 2B ) nor in the infected group treated with foscamet ( Figure 2F ). (25) . It has also been proposed to stop the maintenance therapy in patients undergoing HAART treatment when the following criteria are fulfilled: 1) CD4 count is higher than 150/mm3, 2) there is a negative CMV-PCR and 3) the HIV viral load is lower then 200 copies/ml (26) . However, others have reported that there are still patients under HAART therapy who have a high risk of CMV retinitis relapse (27, 28) . The issue on whether or not to stop maintenance therapy for CMV disease is yet to be defined. In addition, the compliance of patients under triple therapy is poor because of the large number of pills that have to be taken at different times daily. It is clear that there is still a need for an efficient CMV treatment with less systemic side effects, and a more convenient way of administration than daily restricting i.v. perfusions with catheter-related complications.
It is now well recognized that antivirals injected intravenously do not reach the eye in sufficient concentrations to inhibit the viral replication (9, 29) . This observation might explain why there are retinitis relapses in AIDS patients, with a shorter time to progression between each reactivation (30). The low drag concentrations obtained in the eye might also be an important factor for antiviral resistance. In addition, toxicity of foscamet following systemic treatments is a major concern. The main toxicity associated with foscamet treatment is renal impairment mainly manifested by an increase in serum creatinine (4, 11) . Other toxicities caused by foscamet include reversible calcium and phosphorus abnormalities (11, (13) (14) (15) and anemia (13, 16, 17 
